CRISPR Therapeutics partners with Anagenesis Biotechnologies

Press Release, CRISPR Therapeutics,

In an exclusive agreement CRISPR Therapeutics Р founded by Emmanuel Charpentier Рhas licensed Anagenesis Biotechnologies proprietary paraxial mesodermic multipotent cells (P2MCs).  The P2MC technology allows the differentiation of pluripotent cells into skeletal muscle cells allowing for researcher into CRISPR gene therapies.  CRISPR Therapeutics plans to use the technology to study Duchenne Muscular Dystrophy (DMD) therapies.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply